Reproducibility of measurement of myometrial invasion in endometrial carcinoma
- PMID: 27787595
- PMCID: PMC5243868
- DOI: 10.1007/s00428-016-2035-5
Reproducibility of measurement of myometrial invasion in endometrial carcinoma
Abstract
Myometrial invasion (MI) as a percentage (%MI), categorized into <50 or ≥50 %, is an important predictor of prognosis in endometrial carcinoma. Recent studies suggest that tumor-free distance (TFD) to serosa and the absolute depth of invasion (DOI) might be stronger predictors of prognosis. Although reproducibility is important in clinical practice for patient prognostication and treatment, reproducibility of these methods for the measurement of MI is largely unknown. One or two slides from 50 patients with FIGO stage I endometrioid endometrial carcinoma were viewed by seven gynecological pathologists, who were requested to measure %MI, TFD, and DOI. We categorized %MI as <50 % (including no MI) or ≥50 %, TFD as ≤1.75 or >1.75 mm (including no MI), ≤7 or >7 mm (including no MI), and ≤10 or >10 mm (including no MI) and DOI as <4 mm (including no MI) or ≥4 mm. Light's kappa for multi-rater agreement was calculated. The %MI, TFD, and DOI could be measured in 88, 83, and 79 % of cases, respectively. Kappa was 0.75 for %MI, 0.77, 0.73, and 0.69 respectively for TFD with cutoffs of 1.75, 7, and 10 mm, and 0.59 for DOI. Pathologists reach substantial agreement when measuring %MI and TFD and moderate agreement when measuring DOI. The %MI can be measured in more cases than TFD and DOI. This supports the use of %MI in daily clinical practice, but future studies should compare %MI and TFD more extensively, including inter-observer variability.
Keywords: Depth of invasion; Endometrial carcinoma; Inter-observer variability; Myometrial invasion; Tumor-free distance.
Conflict of interest statement
Compliance with ethical standards No ethical approval was needed for this study, which was performed according to the Code for Proper Secondary Use of Human Tissue (Dutch Federation of Biomedical Scientific Societies, www.federa.org). Funding This study was not funded. Conflict of interest The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%.Gynecol Oncol. 2013 May;129(2):285-91. doi: 10.1016/j.ygyno.2013.02.013. Epub 2013 Feb 17. Gynecol Oncol. 2013. PMID: 23422503
-
Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer.BJOG. 2012 Sep;119(10):1162-70. doi: 10.1111/j.1471-0528.2012.03427.x. Epub 2012 Jul 17. BJOG. 2012. PMID: 22804815
-
Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer.Int J Gynecol Cancer. 2010 Oct;20(7):1217-21. doi: 10.1111/igc.0b013e3181ef0a31. Int J Gynecol Cancer. 2010. PMID: 21495232
-
Tumor free distance from serosa and survival rates of endometrial cancer patients: A meta-analysis.Eur J Obstet Gynecol Reprod Biol. 2023 Jul;286:16-22. doi: 10.1016/j.ejogrb.2023.05.001. Epub 2023 May 8. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 37167809 Review.
-
[Clinico-pathological staging of endometrial carcinoma and the evaluation of methods for assessing myometrial invasion in clinical stage I cases].Zhonghua Fu Chan Ke Za Zhi. 1993 Jul;28(7):429-31. Zhonghua Fu Chan Ke Za Zhi. 1993. PMID: 8287728 Review. Chinese. No abstract available.
Cited by
-
Is Tumor-Free Distance an Independent Prognostic Factor for Early-Stage Endometrioid Endometrial Cancer?J Oncol. 2020 Apr 14;2020:2934291. doi: 10.1155/2020/2934291. eCollection 2020. J Oncol. 2020. PMID: 32351565 Free PMC article.
-
Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer.Mol Clin Oncol. 2018 Jul;9(1):87-91. doi: 10.3892/mco.2018.1629. Epub 2018 May 16. Mol Clin Oncol. 2018. PMID: 29896403 Free PMC article.
-
Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.Histopathology. 2019 Jul;75(1):128-136. doi: 10.1111/his.13871. Epub 2019 Jun 10. Histopathology. 2019. PMID: 31155736 Free PMC article. Clinical Trial.
-
MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.Insights Imaging. 2022 Jan 8;13(1):1. doi: 10.1186/s13244-021-01133-z. Insights Imaging. 2022. PMID: 35000020 Free PMC article.
-
Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.Diagn Pathol. 2021 Apr 8;16(1):28. doi: 10.1186/s13000-021-01093-4. Diagn Pathol. 2021. PMID: 33832498 Free PMC article.
References
-
- Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–1411. doi: 10.1016/S0140-6736(00)02139-5. - DOI - PubMed
-
- Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG, Gynecologic Oncology G. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(3):744–751. doi: 10.1016/j.ygyno.2003.11.048. - DOI - PubMed
-
- Group AES, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–146. doi: 10.1016/S0140-6736(08)61767-5. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources